| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/11/1999 | US5902588 Water soluble nonantigenic polymer with a secondary or tertiary amine, spacer moiety and covalent linkage to a nucleophile consisting of proteins and chemotherapeutic agents; improved bioactivity, pi and ph optimum |
| 05/11/1999 | US5902575 Method for treating the epithelium of bodily orifices with chlorine dioxide and a phosphate compound |
| 05/11/1999 | US5902329 Opitimizing the construction of implantable leads and catheters for chronic blood contacting use is realized by a new hydrogel coated leads |
| 05/11/1999 | CA2194610C Sustained-release formulation of animal growth hormone and process for preparation thereof |
| 05/11/1999 | CA2159580C Pharmaceutical compositions containing polyvinylpyrrolidone and a tri-ester and process of manufacture thereof |
| 05/11/1999 | CA2124085C Receptor for oncostatin m and leukemia inhibitory factor |
| 05/11/1999 | CA2098814C Method of producing microscopic particles made of hydrolytically decomposable polymers and containing active substances |
| 05/11/1999 | CA2074162C Composition to improve survival of biological materials |
| 05/11/1999 | CA1340537C Polymer-bonded complexing agents, their complexes and conjugates, processes for their production and pharmaceutical agents containing them |
| 05/07/1999 | CA2228977A1 Localized oligonucleotide therapy for preventing restenosis |
| 05/06/1999 | WO1999021908A1 Polymeric systems for drug delivery and uses thereof |
| 05/06/1999 | WO1999021588A1 Heparin-binding growth factor derivatives |
| 05/06/1999 | WO1999021587A1 Complexing agents and targeting immunoreagents |
| 05/06/1999 | WO1999021586A2 Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions |
| 05/06/1999 | WO1999021585A1 Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate |
| 05/06/1999 | WO1999021579A1 Solid dispersing vaccine composition for oral delivery |
| 05/06/1999 | WO1999021578A1 Insoluble insulin compositions |
| 05/06/1999 | WO1999021573A1 Fatty acid-acylated insulin analogs |
| 05/06/1999 | WO1999021567A1 Pharmaceutical compositions for oral administration of molecular iodine |
| 05/06/1999 | WO1999021548A1 Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 05/06/1999 | WO1999021547A1 Stable solution of zinc and bicarbonate ions |
| 05/06/1999 | WO1999021536A1 Controlled release formulations |
| 05/06/1999 | WO1999021534A1 Solid state solutions and dispersions of poorly water soluble drugs |
| 05/06/1999 | WO1999021531A1 β-D GLUCAN TOPICAL COMPOSITION |
| 05/06/1999 | WO1999012549A3 Controlled release microsphere delivery system |
| 05/06/1999 | EP0913406A1 Glucoamylase converted starch derivatives and their use as emulsifying and encapsulating agents |
| 05/06/1999 | EP0913390A2 Nonionic surfactant |
| 05/06/1999 | EP0913177A1 Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying |
| 05/06/1999 | EP0913159A1 Drug delivery system using galactoxyloglucan |
| 05/06/1999 | EP0913158A1 Transdermal patch comprising a combination of two or more fatty acids or alcohols as permeation enhancers |
| 05/06/1999 | EP0913152A1 Stabilised combination of drugs comprising naloxone and an opioid analgesic |
| 05/06/1999 | EP0913149A1 Drug composition with controlled drug release rate |
| 05/06/1999 | EP0912738A2 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/06/1999 | EP0912730A2 Conjugates of soluble peptidic compounds with membrane-binding agents |
| 05/06/1999 | EP0912729A1 INHIBITION OF CHRONIC MYELOGENOUS LEUKEMIC CELL GROWTH BY LIPOSOMAL-ANTISENSE OLIGODEOXY-NUCLEOTIDES TARGETING TO Grb2 OR Crk1 |
| 05/06/1999 | EP0912627A1 Sustained release heterodisperse hydrogel systems - amorphous drugs |
| 05/06/1999 | EP0912598A1 Steroid bisphosphonates |
| 05/06/1999 | EP0912251A1 A dispensing device and method for forming material |
| 05/06/1999 | EP0912198A1 Immunoliposomes that optimize internalization into target cells |
| 05/06/1999 | EP0912197A2 Haemoglobin-hydroxyethyl starch conjugates as oxygen carriers |
| 05/06/1999 | EP0912187A2 Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts |
| 05/06/1999 | EP0688327B1 Analogs for specific oligosaccharide-protein interactions and uses therefor |
| 05/06/1999 | EP0676953B1 Plasticized bioerodible controlled delivery system |
| 05/06/1999 | EP0574571B1 Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| 05/06/1999 | EP0570519B1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis |
| 05/06/1999 | CA2348922A1 Polymeric systems for drug delivery and uses thereof |
| 05/06/1999 | CA2307891A1 Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 05/06/1999 | CA2307863A1 Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions |
| 05/06/1999 | CA2306905A1 Fatty acid-acylated insulin analogs |
| 05/06/1999 | CA2306877A1 Insoluble insulin compositions |
| 05/06/1999 | CA2304815A1 .beta.-d glucan topical composition |
| 05/05/1999 | CN1215993A Pharmaceutical formulations |
| 05/05/1999 | CN1215989A Dosage form of ibuprofen |
| 05/05/1999 | CN1215988A Ophthalmic compound with extended dwell time on eye |
| 05/05/1999 | CN1215986A Methods for preparing gas-filled liposomes |
| 05/05/1999 | CN1215591A Chroman derivative-containing ophthalmic solution |
| 05/05/1999 | CN1043189C Method for preparing prolonged release preparation |
| 05/04/1999 | US5900461 Conjugation |
| 05/04/1999 | US5900419 Solution or suspension of camptothecin derivative in n-methyl-2-pyrrolidone, pharmaceutically acceptable acid, polyethylene glycol, lower alcohol or benzyl alcohol |
| 05/04/1999 | US5900416 Aqueous caffeine dosage forms |
| 05/04/1999 | US5900412 Percutaneous/transdermal delivery of ASA and antithrombotic therapies based thereon |
| 05/04/1999 | US5900407 Method of treating dry eye disease with uridine triphosphates and related compounds |
| 05/04/1999 | US5900404 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 05/04/1999 | US5900402 Reacting an oxygen-carrying protein (e.g., hemoglobin) with a substantially non-antigenic polymer and administering the conjugate to a mammal |
| 05/04/1999 | US5900252 Multidose minitablet drug cores surrounded by a first polymeric membrane soluble at ph above 5.5 and an outer insoluble membrane which is permeable to gastric fluids, for timed release in ileum or colon |
| 05/04/1999 | US5900250 Monoglyceride/lactate ester permeation enhancer for oxybutnin |
| 05/04/1999 | US5900247 Mucoadhesive pharmaceutical composition for the controlled release of active principles |
| 05/04/1999 | CA2180424C Drugs, vaccines and hormones in polylactide coated microspheres |
| 05/04/1999 | CA2108008C Antimicrobial compositions useful for medical applications |
| 05/04/1999 | CA1340529C Pediatric ibuprofen compositions |
| 05/04/1999 | CA1340526C Interaction system comprising a surfactant-stabilized disperse aqueous phase containing an antibody or antibody fragment |
| 04/30/1999 | CA2252314A1 Use of an enzymatically converted starch derivative as an encapsulating agent |
| 04/29/1999 | WO1999020745A1 Enteric coated microgranules for stabilizing lactic acid bacteria |
| 04/29/1999 | WO1999020310A1 J-chain and analogues as epithelial cell targeting conjugates |
| 04/29/1999 | WO1999020306A1 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| 04/29/1999 | WO1999020305A1 Veterinary vaccines |
| 04/29/1999 | WO1999020296A1 Oral cyclosporin formulations |
| 04/29/1999 | WO1999020283A1 Intra-cancer-cell nuclease activator |
| 04/29/1999 | WO1999020282A1 Progestin therapy with controlled bleeding |
| 04/29/1999 | WO1999020277A1 Rapidly soluble drug composition |
| 04/29/1999 | WO1999020276A1 Stable drug composition |
| 04/29/1999 | WO1999020266A1 Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| 04/29/1999 | WO1999020256A2 Medicament excipient particles for tissue-specific application of a medicament |
| 04/29/1999 | WO1999020255A1 Oral morphine multiparticulate formulation |
| 04/29/1999 | WO1999020254A1 Novel method for obtaining microspheres and resulting products |
| 04/29/1999 | WO1999020253A1 Encapsulation method |
| 04/29/1999 | WO1999020252A1 Particles |
| 04/29/1999 | WO1999020250A1 Topical antifungal composition |
| 04/29/1999 | WO1999020107A1 Improved iodine antimicrobial compositions containing nonionic surfactants and halogen anions |
| 04/29/1999 | WO1999020098A1 Methods for preventing and treating bacterial infections using cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate excipients |
| 04/29/1999 | WO1999006070A9 Switchable viscoelastic systems containing galactomannan polymers and borate |
| 04/29/1999 | WO1999006026A9 Stable particulate complexes with neutral or negative global charge of lamellar structure |
| 04/29/1999 | WO1999003452A9 Methods of removing residual solvent from nasal drug delivery compositions |
| 04/29/1999 | WO1998046274A3 Cationic polymers for nucleic acid transfection |
| 04/29/1999 | CA2649671A1 Progestin therapy for causing endometrial atrophy while maintaining amenorrhea |
| 04/29/1999 | CA2308236A1 Medicament excipient particles for tissue-specific application of a medicament |
| 04/29/1999 | CA2307615A1 Progestin therapy with controlled bleeding |
| 04/29/1999 | CA2306995A1 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| 04/29/1999 | CA2306972A1 Particles |
| 04/29/1999 | CA2306204A1 J-chain and analogues as epithelial cell targeting conjugates |